Adults looking to take advantage of the benefits offered by human growth hormone (HGH) injections may be wondering what dosage is best for them. This can be a difficult question as each individual has ...

The growth hormone is significant for normal body functioning as they regulate the physical, cognitive, and functional aspects. The human body naturally supplements balanced hormones to promote our ...

Novo Nordisk has announced that Sogroya® (somapacitan injection) is now commercially available in Canada. Sogroya® is ...

ORLANDO, Florida — Two investigational long-acting growth-hormone (GH) replacement products hold potential for less frequent dosing and improved adherence among adult patients with proven ...

COPENHAGEN, Denmark, July 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA ® (lonapegsomatropin-tcgd ...

Benefits of growth hormone replacement Some other legally approved uses for human growth hormone replacement therapy include conditions like short-bowel syndrome, where a person can’t absorb nutrients ...

As economic pressure builds to controlcosts, drugs used in relatively smallpopulations will become prime targetsfor cost containment. Drug costs continueto increase yearly (Figure 1), andbecause of ...

August 8, 2012 — Treatment with human growth hormone–releasing hormone (GHRH) for 20 weeks had favorable effects on cognitive function in a randomized controlled trial of healthy older adults and ...

Please provide your email address to receive an email when new articles are posted on . Adults with liver disease receiving GH vs. placebo had a greater increase in IGF-I and decrease in intrahepatic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. All-cause health care costs in adult Medicaid recipients ...

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating ...